Company intelligence / Profile preview

Hangzhou Yirui Pharmaceutical Technology Co., Ltd.

Hangzhou, Zhejiang, Chinayirui-pharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Yirui Pharma’s lead program, YR001—a topical Kv1.3 inhibitor—has completed Phase 1 trials in the US with good safety/tolerability results and has received NMPA approval for clinical trials in China. The company’s pipeline includes several preclinical programs targeting autoimmune/inflammatory indications using novel small molecules.

Therapeutic areas: Men's HealthImmunologyEndocrinology
Modalities: small molecules (notably small molecule inhibitors targeting ion channels and GPCRs)
Industry: Biotech

Drug pipeline

6 assets

YR001

5 more assets in the full pipeline.

Beyond the preview

Go deeper on Hangzhou Yirui Pharmaceutical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Yirui Pharmaceutical Technology Co., Ltd..